The results from the trial showed that Jemperli plus chemotherapy followed by Jemperli and Zejula improved progression-free survival, compared to chemotherapy alone in both the overall patient population and in a subpopulation of patients with certain types of tumours. Progression-free survival refers to how long a patient lives without the disease getting worse after treatment.
If Approved, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Would Offer an up to Once-Monthly Facilitated Subcutaneous…
Any port in a storm will do; fortified wine perfect for any occasion canada.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from canada.com Daily Mail and Mail on Sunday newspapers.
The past year has seen a multitude of FDA approvals, ranging from IL-23 and JAK inhibitors to biologics and subcutaneous treatment administrations, that have helped redefine what it means to treat IBD.
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.